|
Contralateral submandibular gland dose
|
1.06 (1.02–1.10)
|
0.004
|
1.03 (0.98–1.09)
|
0.29
|
|
T4 tumor stage
|
5.99 (1.77–24.18)
|
0.006
|
4.60 (1.17–21.16)
|
0.04
|
|
Superior pharyngeal constrictor dose
|
1.27 (1.09–1.56)
|
0.009
|
1.15 (0.98–1.42)
|
0.12
|
|
Oral cavity dose
|
1.08 (1.01–1.16)
|
0.03
|
1.02 (0.94–1.12)
|
0.62
|
|
Bilateral nodal involvement
|
3.26 (1.02–11.18)
|
0.05
|
1.45 (0.28–7.56)
|
0.65
|
|
Glottic/supraglottic larynx dose
|
1.06 (1.00–1.12)
|
0.06
| | |
|
Parotid glands mean dose
|
1.06 (0.99–1.15)
|
0.11
| | |
|
Inferior pharyngeal constrictor dose
|
1.04 (0.99–1.09)
|
0.13
| | |
|
Middle pharyngeal constrictor dose
|
1.08 (0.98–1.21)
|
0.15
| | |
|
Cricopharyngeal muscle dose
|
1.02 (0.98–1.07)
|
0.35
| | |
|
Age
|
1.02 (0.95–1.10)
|
0.56
| | |
|
Esophageal inlet muscles dose
|
1.01 (0.97–1.05)
|
0.63
| | |
